Reference/Melanocortin receptor agonist

PT-141

Melanocortin Receptor Agonist · Sexual Dysfunction Treatment

Human clinical

research use only

FDA-approved melanocortin receptor agonist for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Works centrally in the nervous system to trigger sexual arousal pathways independent of vascular mechanisms, unlike traditional ED medications.

FDA-approved pharmaceutical routePredictable absorption profileEffective for both male and female sexual dysfunctionWorks within 45 minutes

4 citations·3 with human data·Updated 10 Aug 2026

Overview

Selectively activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of peripheral vascular mechanisms. Works within 45 minutes with effects lasting 6-12 hours.

Evidence profilederived from 4 references

Human clinical

Strongest design among the references on this page. Grade and effect size are separate facts and are never merged into one score.

Research indications

What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.

Sexual Health3

Hypoactive Sexual Desire Disorder (HSDD)

FDA-approved for treatment of HSDD in premenopausal women.

Large

Erectile Dysfunction

Effective in men including PDE5 inhibitor-resistant cases via CNS pathways.

Moderate

Female Sexual Arousal Disorder

Enhances sexual arousal and desire in women.

Moderate

Quality of Life2

Sexual Distress Reduction

Reduces distress related to low sexual desire.

Moderate

Sexual Satisfaction

Enhanced satisfaction reported in clinical trials.

Moderate

A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.

Quick factsreference only

Class: Melanocortin receptor agonist
Half-life: ~2.7 h
Typical dose: Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance
Frequency: As needed before sexual activity; max 1 dose per 24 hours
Cycle length: Use as needed for sexual enhancement
Storage: Refrigerate at 2-8°C, use reconstituted solution within 30 days

Molecular data

Type: Melanocortin receptor agonist
Half-life: 162 min

Dosing reference

Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.

Context	Route	Amount	Frequency
Female HSDD (FDA-approved)	SubQ	1.75mg	As needed, max 1 dose/24hr
Male Erectile Dysfunction	SubQ	1-2mg	As needed, 45-60min before activity
Female Arousal Disorder	SubQ	0.75-1.25mg	As needed, max 1 dose/24hr
Low Starting Dose	SubQ	0.5mg	Test dose for tolerance assessment
Male ED - Standard	Nasal	1.5-2mg	As needed, 30-45min before
Female Sexual Dysfunction	Nasal	1-1.5mg	As needed, max 1 dose/24hr

Interactions

Sildenafil/Tadalafil

PT-141 works centrally; PDE5 inhibitors work peripherally - monitor for additive BP effects.

monitor

Melanotan II

Both are melanocortin agonists; combining risks excessive activation and side effects.

monitor

Blood Pressure Medications

PT-141 can transiently lower blood pressure - monitor closely.

monitor

Alcohol

Both lower BP and cause flushing - limit intake to avoid excessive hypotension.

monitor

Nitrates

Risk of severe hypotension - contraindicated with heart condition medications.

avoid

BPC-157

Different mechanisms; no known interactions.

compatible

Testosterone

May work synergistically for sexual dysfunction through different pathways.

synergistic

Kisspeptin

Different pathways (melanocortin vs GnRH) - no receptor overlap but monitor BP effects.

monitor

Quality checklist

✓FDA-approved pharmaceutical grade (Vyleesi) from licensed pharmacy
✓White crystalline powder (pure PT-141)
✓Clear solution when reconstituted
✓Proper labeling with concentration and purity
!Compounded versions - ensure pharmacy is licensed and follows USP standards
×Colored or oily appearance indicating impurities or degradation
×Cloudy solution after reconstitution
×Unknown source without quality documentation

What to expect

0-30 minutesMild nausea or facial flushing possible

45-90 minutesOnset of effects - increased arousal and desire

2-4 hoursPeak effects - enhanced sexual response

6-12 hoursGradual diminishment of effects

Safety

Commonly reported4

Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions

Stop and seek advice5

Severe or persistent nausea/vomiting
Significant blood pressure drop or dizziness
Chest pain or irregular heartbeat
Severe headache or vision changes
Prolonged erection exceeding 4 hours

Contraindications4

Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding

FAQ

How is PT-141 different from Viagra if both treat erectile dysfunction?

Completely different mechanisms. Viagra (sildenafil) works peripherally by dilating blood vessels in the penis (PDE5 inhibition). PT-141 works centrally in the brain via melanocortin receptors to trigger sexual desire and arousal independent of blood flow. PT-141 can even work in PDE5 inhibitor-resistant cases because it bypasses the vascular system entirely.

Why does PT-141 cause nausea in 40% of people?

PT-141 activates melanocortin receptors broadly in the brain, not just sexual arousal centers. Off-target activation in nausea-control areas is a known side effect. Taking an anti-nausea medication 30 minutes before PT-141 (as recommended in the file) significantly reduces this. Many users find pre-medication worthwhile for the benefit.

Can women use PT-141, or is it only for men?

Women can use it. PT-141 is FDA-approved for female HSDD (hypoactive sexual desire disorder) at 1.75mg. Men use 1-2mg for ED. The mechanism is identical—melanocortin receptor activation increases sexual arousal in both sexes. It's one of the few sexual enhancement drugs with proven efficacy specifically in women.

Is PT-141 safe if I have high blood pressure?

No. PT-141 raises blood pressure and causes flushing. The file lists uncontrolled hypertension as a contraindication. Monitor your BP closely if you have hypertension, and avoid combining with blood pressure-lowering medications. Nitrates are specifically contraindicated due to severe hypotension risk.

References

1
Double-Blind, Placebo-Controlled Evaluation of Intranasal PT-141 in Healthy Males and Patients with Erectile Dysfunction
Diamond LE, Earle DC, Rosen RC, et al. · Urology · 2004
Intranasal PT-141 produced dose-dependent increase in erectile activity at doses >7mg, with onset in ~30 minutes. Safe and well-tolerated in both healthy men and ED patients.
human-rctPubMed 14963471 ↗
2
Salvage of Sildenafil Failures with Bremelanotide: A Randomized, Double-Blind, Placebo-Controlled Study
Safarinejad MR · Journal of Urology · 2008
342 men with ED unresponsive to sildenafil randomized to 10mg bremelanotide intranasal spray vs placebo. Demonstrated effectiveness in PDE5 inhibitor-resistant cases.
human-rctPubMed 18206919 ↗
3
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT)
Kingsberg SA, Clayton AH, Portman D, et al. · Obstetrics & Gynecology · 2019
Two identical phase 3, randomized, double-blind, placebo-controlled trials (NCT02333071 and NCT02338960). Bremelanotide 1.75mg SubQ significantly improved sexual desire and reduced related distress in premenopausal women with HSDD.
human-rctPubMed 31599840 ↗
4
The Neurobiology of Bremelanotide for the Treatment of HSDD in Premenopausal Women
Clayton AH, Kingsberg SA, Goldstein I, et al. · CNS Spectrums · 2021
Bremelanotide activates MC4R in the medial preoptic area of the hypothalamus, increasing dopamine release. CNS mechanism of action independent of peripheral vascular effects.
reviewPubMed 33455598 ↗